Latest News and Press Releases

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that...

The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.

Mabylon has initiated a Phase I clinical trial evaluating its novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy.

4D Path has announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials.

Target enrollment of 2,850 healthy volunteers completed across multiple European countriesTopline data read-out expected by mid-2026, subject to influenza circulation during the winter season  Lyon,...

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation...

FOR IMMEDIATE RELEASE -- ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 -- Updated clinical data presented at ASH show robust efficacy,...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kensington, MD, USA and Munich/Martinsried, Germany, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics...